News & Media: All

Apr 14, 2014

PHE Opens Fifth Office In Austin, Texas

Precision Health Economics is proud to announce the opening of its fifth location—Austin, TX—as part of its continuing expansion plan.  The Austin office will house both research and executive administrative functions. PHE will draw on the city's fertile recruitment pool of highly educated ...

Apr 11, 2014

Philipson Participates in PhRMA Annual Meeting Innovation Discussion

PHE Partner Tomas Philipson participated in PhRMA's 56th Annual meeting held on April 9th, 2014 in Washington, DC-- offering his perspective as a panelist. The panel topic, "The Value of Medical Innovation to Patients, Economies and Society" featured commentary from Dr. Philipson as well as seve ...

Apr, 2014

Forbes April Op-Ed by Tomas Philipson and Dana Goldman: Health Insurance "Double Jeopardy"

PHE partners Tomas Philipson and Dana Goldman team up for their latest Forbes. com Op-Ed: "'Double Jeopardy' in American Health Insurance."

To read the complete article, please click here.

Mar 31, 2014

PHE Taps BMS Executive Ross Maclean As Chief Operating Officer

Precision Health Economics is proud to announce the hiring of Ross Maclean as our chief operating officer (COO). Dr. Maclean's significant and varied background spans the provider, payer, and manufacturing worlds in multiple countries, encompassing leadership skills, management talents, and a ra ...

Mar 28, 2014

PHE Study Cited in US News & World Report

PHE's recent study on the influence of nutritional supplements in hospital readmissions was cited in Robert Miller's Op-Ed for US News & World Report: "Is Nutrition the First Step in Addressing Hospital Readmissions?"

To read the complete article, please click here.

Mar 13, 2014

Goldman In Forbes: Obamacare Not Responsible For Deceleration of Health Care Spending

Dana Goldman and his co-author Sarah Axeen contribute to Forbes.com with "No, Obamacare Isn't Responsible for The Deceleration of US Health Care Spending."

To read the complete article, click here.

Mar 12, 2014

PHE Authors Key Contributors To Health Affairs' HIV Edition

Precision Health Economics authors are prominently featured in the March 2014 edition of Health Affairs, focusing on the ACA and Vulnerable Americans. Seven articles published in the journal feature PHE authors, including:

  • "Early HIV Treatment in The United States Prevented Nearly 13,500 Infe ...

Mar 10, 2014

Philipson Contributes To Special Scientific American Cancer Supplement

Founding Partner Tomas Philipson is a contributor to Scientific American's just-released special cancer supplement: "A World Free From Cancer." Dr. Philipson's perspective is featured in "The Price of Progress: Do the benefits justify the cost?"

To download a complete .pdf copy of the supplemen ...

Mar 6, 2014

PHE's Lakdawalla Appears Before California State Assembly Hearing on Biotechnology

PHE Founding Partner Darius Lakdawalla recently appeared before the California State Assembly, as part of a special hearing on Biotechnology.

Video of Dr. Lakdawalla's testimony is now available online via YouTube and iTunes U. To view please click on the links below:

For iTunes U video, plea ...

Mar 5, 2014

PHE's Philipson and von Eschenbach in Forbes: "Can FDA Be A Life-Boat?"

Tomas Philipson and his co-author, ex-FDA Commissioner Andrew von Eschenbach (currently a Senior Principal Consultant at PHE) contribute their perspective in March's Forbes.com commentary: "The Coming Perfect Storm In Medical Innovation: Can FDA Be A Life-Boat?"

To read the complete commentary, ...

Mar 4, 2014

New York Times Commentary Cites PHE's Philipson

PHE partner Tomas Philipson is cited in this New York Times Commentary by Casey B. Mulligan, Dr. Philipson's colleague at the University of Chicago. The Op-Ed: "The Economics of Randomized Experiments," references Dr. Philipson's suggestions regarding the incentives offered to participants in cl ...

Feb 18, 2014

Join PHE's Julia Snider for a Live Webinar on February 25th

We invite you to join PHE Senior Research Economist Julia Snider at 10am PST on February 25th, 2014 for a live webinar hosted by the American Journal of Health Promotion.

The webinar, moderated by the AJHP's Editor-in-Chief Michael P. O'Donnell, will include a discussion with Julia on her fort ...

Feb 3, 2014

Tomas Philipson in February Forbes.com Commentary: "Don't Be Fooled"

Tomas Philipson's February Forbes.com commentary focuses on the value of generic drugs vs. brand names, and how the development of brand name medications actually contribute more to cost savings and innnovation than their no-name competitors.

Read the complete article here.

Jan 16, 2014

Former FDA Commissioner Andrew von Eschenbach Joins Precision Health Economics Team

Former White House Council of Economic Advisers' Wesley Yin Signs On

Precision Health Economics is proud to announced the addition of two nationally esteemed figures: former Food and Drug Administration (FDA) Commissioner Andrew von Eschenbach, MD, and former Deputy Assistant Secretary of Treas ...

Jan 10, 2014

Dana Goldman's Forbes.com Op-Ed: "Universal Health Coverage At Half the Cost"

PHE Founding Partner Dana Goldman, along with co-author Kip Hagopian, contribute an Op-Ed to Forbes: "How To Achieve Universal Health Coverage At Half The Cost." In their commentary, Goldman and Hagopian examine the ACA and its shortcomings, offering an alternative concept designed to promote un ...

Jan 3, 2014

Tomas Philipson Quoted in The Economist

PHE Fouding Partner Tomas Philipson was quoted in The Economist, January 2014, on the subject of drug development and global pricing: "Hard Pills to Swallow."

Click here to read the complete article.

Jan 3, 2014

PHE's Lakdawalla and Jena in JAMA: UK Cancer Drugs Fund A Careful Use of Science?

JAMA's January 1, 2014 edition features an article written by PHE Founding Partner Darius Lakdawalla, Principal Consultant Anupam "Bapu" Jena, and co-author Jason Doctor, "Careful Use of Science to Advance the Debate on the UK Cancer Drugs Fund."  

Focusing on the current debate between drug ma ...

Jan 3, 2014

Philipson in Forbes: 'Price Controls Are Killing Patients'

Tomas Philipson's latest Forbes.com Op-Ed, "Beyond Economics: How Price Controls Are Killing Millions of Patients" examines the implications price control has on innovation and drug development.

Read the complete Op-Ed here.

Jan 3, 2014

Lakdawalla Interviewed in MedScape: UK 'Exceptionalism' for Cancer Therapy

PHE Founding Partner Darius Lakdawalla was recently interviewed by Medscape on his (along with PHE Principal Consultant Anupam "Bapu" Jena and co-author Jason Doctor) recently published JAMA article examining the existence of the UK Cancer Drugs Fund.

"In a sense, the Cancer Drugs Fund bridges ...

Dec 4, 2013

Philipson in Forbes: Rich Man, Poor Man

Tomas Philipson's December Forbes commentary: "How Much Does Obamacare Help The Poor? Don't Ask The Rich!" examines the metrics used to establish current ACA guidelines, and some misconceptions.  Read the complete article, and "like" Tomas' commentaries (next to his by-line) to automatically be ...

Dec 3, 2013

PHE Partner Lakdawalla Interviewed by Gov. Jon Huntsman

Darius Lakdawalla was interviewed by former Gov. Jon Huntsman (R-Utah) on the web radio program NO LABELS on December 3rd, 2013. Dr. Lakdawalla discusses the implementation of the ACA, insurance exchanges, and the possibilities for improving health care in the US.

To hear the complete interview ...

Nov 8, 2013

Tomas Philipson in Forbes.com: "Healthcare Costs Are Set To Soar"

Tomas Philipson latest Forbes.com editorial "Obamacare Or Not, Helathcare Costs Are Set To Soar," examines how healthcare reform will likely impact the federal deficit, medical innovation, and the future course of world returns.

To read the commentary, please click here.